Literature DB >> 19398572

Margin clearance and outcome in resected pancreatic cancer.

David K Chang1, Amber L Johns, Neil D Merrett, Anthony J Gill, Emily K Colvin, Christopher J Scarlett, Nam Q Nguyen, Rupert W L Leong, Peter H Cosman, Mark I Kelly, Robert L Sutherland, Susan M Henshall, James G Kench, Andrew V Biankin.   

Abstract

PURPOSE: Current adjuvant therapies for pancreatic cancer (PC) are inconsistently used and only modestly effective. Because a high proportion of patients who undergo resection for PC likely harbor occult metastatic disease, any adjuvant trials assessing therapies such as radiotherapy directed at locoregional disease are significantly underpowered. Stratification based on the probability (and volume) of residual locoregional disease could play an important role in the design of future clinical trials assessing adjuvant radiotherapy. PATIENTS AND METHODS: We assessed the relationships between margin involvement, the proximity to operative resection margins and outcome in a cohort of 365 patients who underwent operative resection for PC.
RESULTS: Microscopic involvement of a resection margin by tumor was associated with a poor prognosis. Stratifying the minimum clearance of resection margins by 0.5-mm increments demonstrated that although median survival was no different to clear margins based on these definitions, it was not until the resection margin was clear by more than 1.5 mm that optimal long-term survival was achieved.
CONCLUSION: These data demonstrate that a margin clearance of more than 1.5 mm is important for long-term survival in a subgroup of patients. More aggressive therapeutic approaches that target locoregional disease such as radiotherapy may be beneficial in patients with close surgical margins. Stratification of patients for entry onto future clinical trials based on this criterion may identify those patients who benefit from adjuvant radiotherapy.

Entities:  

Mesh:

Year:  2009        PMID: 19398572     DOI: 10.1200/JCO.2008.20.5104

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  101 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Resection margins in pancreatic cancer: are we entering a new era?

Authors:  Caroline S Verbeke
Journal:  HPB (Oxford)       Date:  2014-01       Impact factor: 3.647

3.  FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

Authors:  Tanios Bekaii-Saab; Richard M Goldberg
Journal:  Oncologist       Date:  2013

Review 4.  Resection margins in pancreatic cancer.

Authors:  C S Verbeke
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  [New S3 guidelines on exocrine pancreatic cancer].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

6.  Pancreaticoduodenal resection for malignancy in a low-volume center: long-term outcomes from a developing country.

Authors:  Abu Bakar Hafeez Bhatti; Mohammad Aasim Yusuf; Syed Ather Saeed Kazmi; Aamir Ali Syed
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

7.  Management of pancreatic cancer: current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-11-16       Impact factor: 0.656

8.  TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells.

Authors:  Daniel Borja-Cacho; Yumi Yokoyama; Rohit K Chugh; Nameeta R Mujumdar; Vikas Dudeja; Kimberly A Clawson; Rajinder K Dawra; Ashok K Saluja; Selwyn M Vickers
Journal:  J Gastrointest Surg       Date:  2009-12-16       Impact factor: 3.452

9.  Pancreaticoduodenectomy with combined superior mesenteric vein resection without reconstruction is possible: A case report and review of the literature.

Authors:  Lionel Jouffret; Theophile Guilbaud; Olivier Turrini; Jean-Robert Delpero
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

10.  Effective endovascular stenting of malignant portal vein obstruction in pancreatic cancer.

Authors:  Christian M Ellis; Sadashiv Shenoy; Alan Litwin; Stephanie Soehnlein; John F Gibbs
Journal:  HPB Surg       Date:  2009-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.